Pharming Group NV
PHAR18.090USD
+0.850+4.93%
Close 12/24, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Pharming Group NV Company
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Pharming Group NV Info
Ticker SymbolPHAR
Company namePharming Group NV
IPO dateJul 02, 1998
CEOChouraqui (Fabrice)
Number of employees- -
Security typeDepository Receipt
Fiscal year-end- -
AddressDarwinweg 24
CityLEIDEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code2333 CR
Phone31715247400
Websitehttps://www.pharming.com/
Ticker SymbolPHAR
IPO dateJul 02, 1998
CEOChouraqui (Fabrice)
Company Executives of Pharming Group NV
Name
Name/Position
Position
Shareholding
Change
Mr. Kenneth Lynard
Mr. Kenneth Lynard
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Fabrice Chouraqui
Mr. Fabrice Chouraqui
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. Alexander Breidenbach
Dr. Alexander Breidenbach
Chief Business Officer
Chief Business Officer
--
--
Ms. Ines Bernal
Ms. Ines Bernal
Chief People Officer
Chief People Officer
--
--
Mr. Steven Baert
Mr. Steven Baert
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jabine Van Der Meijs
Ms. Jabine Van Der Meijs
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Leonard Kruimer, CPA
Mr. Leonard Kruimer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Anurag Relan, M.D.
Dr. Anurag Relan, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mrs. Mireille Sanders
Mrs. Mireille Sanders
Chief Operations Officer
Chief Operations Officer
--
--
Dr. Mark J. Pykett, M.D., Ph.D.
Dr. Mark J. Pykett, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kenneth Lynard
Mr. Kenneth Lynard
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Fabrice Chouraqui
Mr. Fabrice Chouraqui
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. Alexander Breidenbach
Dr. Alexander Breidenbach
Chief Business Officer
Chief Business Officer
--
--
Ms. Ines Bernal
Ms. Ines Bernal
Chief People Officer
Chief People Officer
--
--
Mr. Steven Baert
Mr. Steven Baert
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jabine Van Der Meijs
Ms. Jabine Van Der Meijs
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Silverberg Bernstein Capital Management, LLC
0.08%
Other
99.92%
Shareholders
Shareholders
Proportion
Silverberg Bernstein Capital Management, LLC
0.08%
Other
99.92%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.08%
Other
99.92%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
13
60.14K
0.09%
-9.65K
2025Q2
10
57.25K
0.08%
-7.99K
2025Q1
11
75.56K
0.11%
-12.14K
2024Q4
11
75.65K
0.11%
-65.36K
2024Q3
11
69.30K
0.10%
-54.56K
2024Q2
9
52.15K
0.08%
-64.69K
2024Q1
9
45.12K
0.07%
-72.64K
2023Q4
9
45.06K
0.07%
-55.56K
2023Q3
9
38.77K
0.06%
-67.63K
2023Q2
10
27.05K
0.04%
-248.66K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Silverberg Bernstein Capital Management, LLC
52.15K
0.08%
--
--
Sep 30, 2025
Morgan Stanley Smith Barney LLC
2.50K
0%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
2.09K
0%
--
--
Aug 31, 2025
Morgan Stanley & Co. LLC
400.00
0%
--
--
Jun 30, 2025
EverSource Wealth Advisors, LLC
2.98K
0%
+2.98K
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Pharming Group NV?
The top five shareholders of Pharming Group NV are:
Silverberg Bernstein Capital Management, LLC holds 52.15K shares, accounting for 0.08% of the total shares.
Morgan Stanley Smith Barney LLC holds 2.50K shares, accounting for 0.00% of the total shares.
Geode Capital Management, L.L.C. holds 2.09K shares, accounting for 0.00% of the total shares.
Morgan Stanley & Co. LLC holds 400.00 shares, accounting for 0.00% of the total shares.
EverSource Wealth Advisors, LLC holds 2.98K shares, accounting for 0.00% of the total shares.
Silverberg Bernstein Capital Management, LLC holds 52.15K shares, accounting for 0.08% of the total shares.
Morgan Stanley Smith Barney LLC holds 2.50K shares, accounting for 0.00% of the total shares.
Geode Capital Management, L.L.C. holds 2.09K shares, accounting for 0.00% of the total shares.
Morgan Stanley & Co. LLC holds 400.00 shares, accounting for 0.00% of the total shares.
EverSource Wealth Advisors, LLC holds 2.98K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Pharming Group NV?
The top three shareholder types of Pharming Group NV are:
Silverberg Bernstein Capital Management, LLC
Other
Silverberg Bernstein Capital Management, LLC
Other
How many institutions hold shares of Pharming Group NV (PHAR)?
As of 2025Q3, 13 institutions hold shares of Pharming Group NV, with a combined market value of approximately 60.14K, accounting for 0.09% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.00%.
What is the biggest source of revenue for Pharming Group NV?
In --, the -- business generated the highest revenue for Pharming Group NV, amounting to -- and accounting for --% of total revenue.
